In observance of World AIDS Day, HIV experts discussed the future of the epidemic with community members at the Smithsonian’s National Museum of Natural History in Washington, D.C. Co-hosted by the American Society for Microbiology, “Imagining an HIV-Free Future” was one in a series of programs related to the new exhibition, Outbreak: Epidemics in a Connected World.
The safety and dosing requirements of a new drug licensed for use by nonpregnant adults may differ for pregnant women. This has been the case for drugs for treating both HIV and tuberculosis (TB), the most common HIV co-infection. An NIH study into how pregnancy affects the body’s processing of drugs for HIV and TB has helped provide a foundation for national and international HIV treatment guidelines for women who are pregnant or have recently given birth.
HIV is a master of sneaking past our natural defenses. Typically, when the body encounters a harmful virus, immune cells recognize viral proteins and stimulate the production of antibodies. HIV, however, has evolved several ways to cloak vulnerable areas of viral proteins. A report released last month from NIAID scientists reveals new insights into one such tactic of immune invisibility.
Scientists have previously recognized that the HIV reservoir varies in size between individuals. Now, NIAID researchers and their collaborators have discovered that variations in an important viral gene may play a role in the size of one’s HIV reservoir. Their findings, reported online last week, expand scientists’ understanding of how specific attributes of the virus a person acquires can affect the course and nature of their HIV infection.
NIAID’s HIV/AIDS Flickr album features a collection of downloadable HIV-related images, including infographics, microscopy images, photographs of HIV researchers and molecular models. These images are public domain and can be freely re-used. Please credit the National Institute of Allergy and Infectious Diseases.
At this week's HIV Research for Prevention (HIV R4P) conference in Madrid, scientists have reported progress in numerous areas of HIV prevention research. NIAID-supported scientists highlighted the need to expand HIV prevention and treatment services among populations greatly affected by HIV, described early findings from a study assessing the safety of a vaginal ring containing both an anti-HIV drug and a birth-control agent, and reported the added benefits of an intervention designed to facilitate treatment for HIV and injection drug use.
A durable end to the HIV/AIDS pandemic will require the development and widespread implementation of new and improved HIV prevention tools, according to NIAID Director Anthony S. Fauci, M.D. Yesterday, Dr. Fauci delivered a plenary lecture at the opening session of the HIV Research for Prevention (HIV R4P) conference, which is taking place this week in Madrid.
Some people treated with antiretroviral therapy after HIV has already significantly damaged the immune system may develop a serious condition called HIV-associated immune reconstitution syndrome, or IRIS. Now, researchers from NIAID and the NIH Clinical Center are working together to visualize and predict this common complication of HIV in a new way—with positron emission tomography, or PET.
The gut microbiome—the community of bacteria and other microbes naturally present in the gastrointestinal tract—plays a critical role in human health. NIAID Now spoke with senior investigator Jason Brenchley, Ph.D., about the link between the gut microbiome and HIV infection, and his lab’s recent research findings.
HIV.gov wrapped up their series of conversations with NIAID's Carl Dieffenbach, Ph.D., about scientific highlights from the 22nd International AIDS Conference (AIDS 2018) as the conference began to wind down.
As part of HIV.gov's series of Facebook Live dispatches from the 22nd International AIDS Conference in Amsterdam, Carl Dieffenbach, Ph.D., shared highlights from the conference's second full day of HIV research presentations.
As the 22nd International AIDS Conference (AIDS 2018) got underway in Amsterdam, HIV.gov began coverage of HIV research advances and other conference highlights with a Facebook Live interview with NIAID Director Anthony S. Fauci, M.D.
The first full day of sessions at the 22nd International AIDS Conference (AIDS 2018) in Amsterdam was filled with new scientific findings shared by researchers from around the world. In a Facebook Live interview with HIV.gov, Carl Dieffenbach, Ph.D., discussed highlights of three studies presented today at the conference.
People living with HIV whose virus is completely, durably suppressed by treatment will not sexually transmit the virus to an HIV-negative partner, according to NIAID Director Anthony S. Fauci, M.D. The success of this HIV prevention strategy is contingent on achieving and maintaining an undetectable viral load by taking HIV medication daily as directed. Dr. Fauci delivered these remarks at the "U=U 2018: Celebrate, Activate and Implement!" meeting held prior to AIDS 2018.
Why do we lack a cure for HIV infection, and what research is underway to help achieve that goal? A new video from NIAID provides answers.
A clinical trial comparing three chemotherapy regimens in combination with antiretroviral treatment for treatment of advanced AIDS-Kaposi’s sarcoma patients in Africa and South America has ended early.
The Broadway and Hollywood star, a lifelong advocate of health and gender equity, graced the stage of NIH’s Ruth Kirschstein Auditorium on May 15 to give the annual J. Edward Rall Cultural Lecture, named for former Deputy Director for Intramural Research Joseph “Ed” Rall. Streisand took the opportunity to highlight an issue that is — literally — near and dear to her heart: women’s cardiovascular health.
HIV-related heart disease is a leading cause of death among people living with HIV—even when they are on consistent, effective HIV treatment. Researchers are learning that this complication is likely brought on by chronic inflammation from the virus itself and other factors. What is less understood is why HIV seems to take a greater toll on the hearts of women.
Most people living with HIV have a single genetic strain of the virus, but in certain cases, a person can acquire a second strain of HIV—a condition known as HIV superinfection. In a new study published online today in the Journal of Infectious Diseases, NIAID researchers and scientists at the Uganda Virus Research Institute describe a case of HIV superinfection they were able to identify with unique precision.
Our coverage from the 2018 Conference on Retroviruses and Opportunistic Infections (CROI) in Boston wrapped up yesterday with two interviews with Federal HIV leaders who shared perspectives about the science coming out of the conference and its implications for HIV prevention, care, and treatment.
During the second full day at the Conference on Retroviruses and Opportunistic Infections in Boston, NIAID’s Anne Rancourt conducted Facebook Live interviews with three leaders from the Department of Health and Human Services about HIV research highlights and their implications.
Advances in HIV research are being shared this week at the 2018 Conference on Retroviruses and Opportunistic Infections (CROI) in Boston. HIV.gov conducted a Facebook Live interview with NIAID’s Dr. Carl Dieffenbach on Monday afternoon to learn about some of the key research findings presented during the first full day of sessions.
A woman’s risk of acquiring HIV through sex with a male partner living with HIV increases during pregnancy and is highest during the postpartum period, new research funded in part by NIAID suggests. Researchers observed this trend of increased risk of HIV transmission per sex act even after taking into account behavioral factors, such as use of condoms or PrEP. The findings suggest that biological changes during and after pregnancy may increase a woman’s HIV risk.
NIAID scientists have demonstrated that a slight change to a powerful, naturally occurring HIV antibody helps it last longer in the human body while counteracting the virus just as well in the laboratory. These characteristics could reduce the cost and increase the convenience of giving people antibodies for HIV prevention because fewer doses of an antibody could achieve the same protective effect.
Today marks not just a time to exchange valentines and chocolates, but also the midpoint of American Heart Month. Did you know people living with HIV are at an increased risk of experiencing cardiovascular disease? Fortunately, NIH-supported research is getting to the heart of the problem.
NIAID makes many resources available to researchers, such as reagents, model organisms, and tissue samples. Now it’s even easier to find these resources on our site using the Resources for Researchers feature.
To make additional HIV prevention options a reality, NIAID supports research on a variety of innovative, long-acting HIV prevention products that could be inserted in the vagina, injected or implanted from once a month to once a year by people who commit to use them on an ongoing basis. These products include a vaginal ring that also delivers contraception.
NIH-funded researchers are developing and testing HIV prevention products that may become alternatives to a daily pill.
Daily antiretroviral therapy can reduce the amount of HIV in the blood to levels that are undetectable with standard tests. Staying on treatment is crucial to keep the virus suppressed. NIAID-supported research has demonstrated that achieving and maintaining a “durably undetectable” viral load (the amount of HIV in the blood) not only preserves the health of the person living with HIV, but also prevents sexual transmission of the virus to an HIV-negative partner.
A short animation explains how HIV hijacks the cellular protein alpha-4 beta-7 to home to the gut and establish infection in this organ system, which harbors one of the richest populations of HIV target cells in the body.
Today marks the 10th National HIV/AIDS and Aging Awareness Day. This annual observance brings attention to the unique social and health-related challenges of older people living with and at risk for HIV. NIAID supports and collaborates on research that aims to both understand and mitigate long-term complications of HIV for men and women aging with HIV.
Ensuring a durable end to the HIV pandemic will require a safe and effective HIV vaccine. A whiteboard video explains how an HIV vaccine could be developed, while focusing on a vaccine currently being tested in a large, NIAID-funded clinical trial in South Africa called HVTN 702.
Development of a safe and effective preventive HIV vaccine remains key to realizing a durable end to the HIV/AIDS pandemic.